These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 34467026)

  • 1. Management of Hepatitis C in Delaware Prisons: : Approaching Microenvironmental Eradication.
    Mazur WP
    Dela J Public Health; 2019 May; 5(2):20-27. PubMed ID: 34467026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Family Practitioner-Directed Hepatitis C Therapy With Direct-Acting Antivirals Achieves High-Sustained Virologic Response in Prison Population.
    Mokkarala S; Johnson C; Sarkar S; Rudas RJ
    J Correct Health Care; 2019 Apr; 25(2):134-142. PubMed ID: 30866706
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes of a nurse-led model of care for hepatitis C assessment and treatment with direct-acting antivirals in the custodial setting.
    Overton K; Clegg J; Pekin F; Wood J; McGrath C; Lloyd A; Post JJ
    Int J Drug Policy; 2019 Oct; 72():123-128. PubMed ID: 30967329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High rate of sustained virological response with direct-acting antivirals in haemophiliacs with HCV infection: A multicenter study.
    Mancuso ME; Linari S; Santagostino E; Bartolozzi D; D'Ambrosio R; Borghi M; Lampertico P; Peyvandi F; Castaman G; Aghemo A
    Liver Int; 2020 May; 40(5):1062-1068. PubMed ID: 31876354
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of cost-effectiveness of peginterferon plus ribavirin for chronic hepatitis C treatment and direct-acting antiviral agents among HIV-infected patients in the prison and community settings.
    Chen CP; Cheng CY; Zou H; Cheng CH; Cheng SH; Chen CK; Chen CH; Bair MJ
    J Microbiol Immunol Infect; 2019 Aug; 52(4):556-562. PubMed ID: 30360951
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urgency to treat patients with chronic hepatitis C in Asia.
    Kao JH; Ahn SH; Chien RN; Cho M; Chuang WL; Jeong SH; Liu CH; Paik SW
    J Gastroenterol Hepatol; 2017 May; 32(5):966-974. PubMed ID: 28005275
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct-Acting Antivirals in Hepatitis C Virus-Associated Diffuse Large B-cell Lymphomas.
    Merli M; Frigeni M; Alric L; Visco C; Besson C; Mannelli L; Di Rocco A; Ferrari A; Farina L; Pirisi M; Piazza F; Loustaud-Ratti V; Arcari A; Marino D; Sica A; Goldaniga M; Rusconi C; Gentile M; Cencini E; Benanti F; Rumi MG; Ferretti VV; Grossi P; Gotti M; Sciarra R; Tisi MC; Cano I; Zuccaro V; Passamonti F; Arcaini L
    Oncologist; 2019 Aug; 24(8):e720-e729. PubMed ID: 30552159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of hepatitis C treatment-as-prevention within Australian prisons (SToP-C): a prospective cohort study.
    Hajarizadeh B; Grebely J; Byrne M; Marks P; Amin J; McManus H; Butler T; Cunningham EB; Vickerman P; Martin NK; McHutchison JG; Brainard DM; Treloar C; Chambers GM; Grant L; Mcgrath C; Lloyd AR; Dore GJ;
    Lancet Gastroenterol Hepatol; 2021 Jul; 6(7):533-546. PubMed ID: 33965006
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs.
    Llaneras J; Riveiro-Barciela M; Lens S; Diago M; Cachero A; García-Samaniego J; Conde I; Arencibia A; Arenas J; Gea F; Torras X; Luis Calleja J; Antonio Carrión J; Fernández I; María Morillas R; Rosales JM; Carmona I; Fernández-Rodríguez C; Hernández-Guerra M; Llerena S; Bernal V; Turnes J; González-Santiago JM; Montoliu S; Figueruela B; Badia E; Delgado M; Fernández-Bermejo M; Iñarrairaegui M; Pascasio JM; Esteban R; Mariño Z; Buti M
    J Hepatol; 2019 Oct; 71(4):666-672. PubMed ID: 31203153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of HCV infection in the penitentiary setting in the direct-acting antivirals era: practical recommendations from an expert panel.
    Ranieri R; Starnini G; Carbonara S; Pontali E; Leo G; Romano A; Panese S; Monarca R; Prestileo T; Barbarini G; Babudieri S;
    Infection; 2017 Apr; 45(2):131-138. PubMed ID: 28025726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Previous incarceration impacts access to hepatitis C virus (HCV) treatment among HIV-HCV co-infected patients in Canada.
    Kronfli N; Nitulescu R; Cox J; Moodie EE; Wong A; Cooper C; Gill J; Walmsley S; Martel-Laferrière V; Hull MW; Klein MB;
    J Int AIDS Soc; 2018 Nov; 21(11):e25197. PubMed ID: 30460791
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV-coinfected patients respond worse to direct-acting antiviral-based therapy against chronic hepatitis C in real life than HCV-monoinfected individuals: a prospective cohort study.
    Neukam K; Morano-Amado LE; Rivero-Juárez A; Mancebo M; Granados R; Téllez F; Collado A; Ríos MJ; de Los Santos-Gil I; Reus-Bañuls S; Vera-Méndez F; Geijo-Martínez P; Montero-Alonso M; Suárez-Santamaría M; Pineda JA
    HIV Clin Trials; 2017 May; 18(3):126-134. PubMed ID: 28599618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. All Oral Interferon-free Direct-acting Antivirals as Combination Therapies to Cure Hepatitis C.
    Shahid I; Ibrahim MM
    Curr Mol Med; 2018; 18(7):409-435. PubMed ID: 30608042
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronic Hepatitis C Virus Infection After Kidney Transplantation With or Without Direct-Acting Antivirals in a Real-Life Setting: A French Multicenter Experience.
    Chevallier E; Büchler M; Caillard S; Bouvier N; Colosio C; Rivalan J; Sayegh J; Bertrand D; Le Meur Y; Thierry A; Garrouste C; Rerolle JP; Rostaing L; Gatault P
    Transplant Proc; 2020 Dec; 52(10):3179-3185. PubMed ID: 32636068
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of HCV eradication by direct-acting antivirals on the transition of precancerous hepatic nodules to HCC: A prospective observational study.
    Toyoda H; Kumada T; Tada T; Mizuno K; Sone Y; Akita T; Tanaka J; Johnson PJ
    Liver Int; 2019 Mar; 39(3):448-454. PubMed ID: 30312003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors for Fibrosis Regression in Chronic HCV Patients after the Treatment with DAAS: Results of a Real-world Cohort Study.
    Soliman H; Ziada D; Salama M; Hamisa M; Badawi R; Hawash N; Selim A; Abd-Elsalam S
    Endocr Metab Immune Disord Drug Targets; 2020; 20(1):104-111. PubMed ID: 31448717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients.
    Cabibbo G; Celsa C; Calvaruso V; Petta S; Cacciola I; Cannavò MR; Madonia S; Rossi M; Magro B; Rini F; Distefano M; Larocca L; Prestileo T; Malizia G; Bertino G; Benanti F; Licata A; Scalisi I; Mazzola G; Di Rosolini MA; Alaimo G; Averna A; Cartabellotta F; Alessi N; Guastella S; Russello M; Scifo G; Squadrito G; Raimondo G; Trevisani F; Craxì A; Di Marco V; Cammà C;
    J Hepatol; 2019 Aug; 71(2):265-273. PubMed ID: 30959157
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous DAA failure.
    Degasperi E; Spinetti A; Lombardi A; Landonio S; Rossi MC; Pasulo L; Pozzoni P; Giorgini A; Fabris P; Romano A; Lomonaco L; Puoti M; Vinci M; Gatti F; Carolo G; Zoncada A; Bonfanti P; Russo FP; Aghemo A; Soria A; Centenaro R; Maggiolo F; Rovere P; Pasin F; Paon V; Faggiano G; Vario A; Grossi G; Soffredini R; Carriero C; Paolucci S; Noventa F; Alberti A; Lampertico P; Fagiuoli S;
    J Hepatol; 2019 Dec; 71(6):1106-1115. PubMed ID: 31433303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Developing a multidisciplinary HCV direct-acting antivirals utilization management and assessment program.
    Ajlan AA; Al-Gain R; Ahmed M; Abu-Riash T; Alquaiz M; Alkhail FA; Alashgar H; Alkhairallah T; Alkortas D; Al-Jedai A
    J Am Pharm Assoc (2003); 2021; 61(2):e159-e170. PubMed ID: 33309191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis C Virus Eradication with New Interferon-Free Treatment Improves Metabolic Profile in Hepatitis C Virus-Related Liver Transplant Recipients.
    Beig J; Orr D; Harrison B; Gane E
    Liver Transpl; 2018 Aug; 24(8):1031-1039. PubMed ID: 29577581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.